ES2003293A6 - Procedimiento de obtencion de 5-arilalquil-4-alcoxy-2(5h)-furanonas - Google Patents

Procedimiento de obtencion de 5-arilalquil-4-alcoxy-2(5h)-furanonas

Info

Publication number
ES2003293A6
ES2003293A6 ES8701330A ES8701330A ES2003293A6 ES 2003293 A6 ES2003293 A6 ES 2003293A6 ES 8701330 A ES8701330 A ES 8701330A ES 8701330 A ES8701330 A ES 8701330A ES 2003293 A6 ES2003293 A6 ES 2003293A6
Authority
ES
Spain
Prior art keywords
new
well
furanonas
alcoxi
treo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8701330A
Other languages
English (en)
Inventor
Chatterjee Shyam Sunder
Klaus Klessing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Dr Willmar Schwabe GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Willmar Schwabe GmbH and Co KG filed Critical Dr Willmar Schwabe GmbH and Co KG
Publication of ES2003293A6 publication Critical patent/ES2003293A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)

Abstract

5-ARILALQUIL-4-ALCOXI-2-5H- FURANONAS, PRODUCTOS INTERMEDIOS Y PROCEDIMIENTO PARA SU FABRICACION, ASI COMO SU UTILIZACION COMO PRODUCTOS ACTIVOS TERAPEUTICOS. SE PROPONEN NUEVAS 5-ARILALQUIL-4-ALCOXI-2-5H- FURANONAS CON UNA FUNCION OXIGENO EN POSICION A DE LA CADENA LATERAL ARILALQUILO, EN LAS CUALES LOS ATOMOS DE OXIGENO EN C-5 Y C-A ADOPTAN LA CONFIGURACION TREO. UN PROCEDIMIENTO NUEVO, QUE CONDUCE ESTEREOSELECTIVAMENTE A LOS TREO-DIASTEREOMEROS DE ESTOS COMPUESTOS SE PATENTARA EN SU CASO. SE PATENTAN ADEMAS NUEVOS 3-ALCOXI-5- (SUBST.)FENIL-2-E-,4-3- PENTADIENOATOS COMO PRODUCTOS INTERMEDIOS REACTIVOS PARA LA FABRICACION DE LOS NUEVOS DERIVADOS FURANONA. LOS NUEVOS DERIVADOS FURANONA DE LA SERIE TREO SON EFICACES ANTICONVULSIVA-ANTIEPILEPTICAMENTE. EL INVENTO SE REFIERE POR LO TANTO TAMBIEN A MEDICAMENTOS QUE CONTIENEN ESTOS NUEVOS DERIVADOS FURANONA O BIEN FURANONAS CONOCIDAS CUYA ACCION ANTICONVULSIVA-ANTIEPILEPTICA SE DETERMINO POR PRIMERA VEZ.
ES8701330A 1986-05-05 1987-05-04 Procedimiento de obtencion de 5-arilalquil-4-alcoxy-2(5h)-furanonas Expired ES2003293A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863615157 DE3615157A1 (de) 1986-05-05 1986-05-05 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe

Publications (1)

Publication Number Publication Date
ES2003293A6 true ES2003293A6 (es) 1988-10-16

Family

ID=6300199

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8701330A Expired ES2003293A6 (es) 1986-05-05 1987-05-04 Procedimiento de obtencion de 5-arilalquil-4-alcoxy-2(5h)-furanonas

Country Status (24)

Country Link
US (1) US4855320A (es)
EP (1) EP0247320B1 (es)
JP (1) JPH0764835B2 (es)
KR (1) KR950001790B1 (es)
CN (1) CN1016868B (es)
AR (1) AR247203A1 (es)
AT (1) ATE59386T1 (es)
AU (1) AU596175B2 (es)
CA (1) CA1270256A (es)
CS (1) CS274728B2 (es)
DD (1) DD260699A5 (es)
DE (2) DE3615157A1 (es)
DK (1) DK166725B1 (es)
EG (1) EG18151A (es)
ES (1) ES2003293A6 (es)
FI (1) FI871946A7 (es)
HU (1) HU206105B (es)
MX (1) MX27046A (es)
NO (1) NO171273C (es)
NZ (1) NZ220188A (es)
PT (1) PT84824B (es)
SU (1) SU1650009A3 (es)
YU (1) YU46422B (es)
ZA (1) ZA872867B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149705A (en) * 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5234926A (en) * 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5037811A (en) * 1990-04-17 1991-08-06 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5043457A (en) * 1990-04-17 1991-08-27 Allergan, Inc. 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents
US5081147A (en) * 1990-03-15 1992-01-14 Allergan, Inc. 4-(1-hydroxy-2-substituted amino)ethyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5059611A (en) * 1988-11-18 1991-10-22 Allergan, Inc. Anti-inflammatory 5-hydroxy-2-furanones
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
DE3737399A1 (de) * 1987-11-04 1989-05-18 Schwabe Willmar Gmbh & Co Aminosaeureester, verfahren zu ihrer herstellung und ihre verwendung
KR0139216B1 (ko) * 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
US5231113A (en) * 1988-04-11 1993-07-27 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
DE59006113D1 (de) * 1989-07-20 1994-07-21 Lonza Ag Verfahren zur Herstellung von Tetronsäurealkylestern.
US5248777A (en) * 1989-09-19 1993-09-28 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5053523A (en) * 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5272156A (en) * 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) * 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5264456A (en) * 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5175185A (en) * 1989-12-29 1992-12-29 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5081261A (en) * 1990-03-23 1992-01-14 Allergan, Inc. 4-(1-hydroxy-2-N-substituted sulfonamido) ethyl-5-hydroxy-2(5H)-furanones and 4-(N-substituted sulfonamido)-2-ethenyl-5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents
ATE150016T1 (de) * 1990-12-20 1997-03-15 Lonza Ag Verfahren zur herstellung von threo-4-alkoxy-5- (arylhydroxymethyl)-2(5h)-furanonen
CA2101160A1 (en) * 1991-02-13 1992-08-14 Roshantha A. Chandraratna Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
IE920949A1 (en) * 1991-03-26 1992-10-07 Allergan Inc Chromans and thiochromans with heteroarylethynyl¹substituents at the 7-position having retinoid-like¹biological activity
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
WO1993016067A1 (en) * 1992-02-11 1993-08-19 Allergan, Inc. Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US6492413B2 (en) 1993-01-15 2002-12-10 G.D. Searle & Co. 3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US6172115B1 (en) 1993-02-11 2001-01-09 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5344959A (en) * 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5475022A (en) * 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5426118A (en) * 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5470999A (en) * 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5451605A (en) * 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
US5498755A (en) * 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618931A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5952345A (en) * 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
AU7598596A (en) * 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US20030219832A1 (en) * 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5747542A (en) * 1996-06-21 1998-05-05 Allergan Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US6555690B2 (en) 1996-06-21 2003-04-29 Allergan, Inc. Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5741896A (en) 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6756414B2 (en) * 1999-07-30 2004-06-29 Sanyo Chemical Industries, Ltd. Polymer polyol composition, process for producing the same, and process for producing polyurethane resin
CN1182127C (zh) * 2000-06-28 2004-12-29 中国医学科学院药物研究所 新的取代的2-苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物
US6387951B1 (en) 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6369261B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
CN1106393C (zh) * 2000-12-19 2003-04-23 中国科学院上海有机化学研究所 一种具有光学活性的β－芳基取代－2（5H）－呋喃酮及其合成方法
FR2845087B1 (fr) * 2002-10-01 2004-12-24 Merck Sante Sas Nouveaux acides arylhexadienoiques substitues et leurs esters,utilisables dans le traitement et la prevention du diabete, des dyslipidemies,de l'atherosclerose, compositions pharmaceutiques les contenant et procedes de preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1920176A1 (de) * 1969-04-21 1970-10-22 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von Hydroxycrotonsaeurelaktonen
JPS5916884A (ja) * 1982-07-19 1984-01-28 Fujisawa Pharmaceut Co Ltd 新規フラン化合物
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤

Also Published As

Publication number Publication date
FI871946L (fi) 1987-11-06
MX27046A (es) 1994-01-31
NO171273B (no) 1992-11-09
DK166725B1 (da) 1993-07-05
ZA872867B (en) 1987-11-25
YU77687A (en) 1988-08-31
JPH0764835B2 (ja) 1995-07-12
FI871946A7 (fi) 1987-11-06
CS274728B2 (en) 1991-10-15
FI871946A0 (fi) 1987-05-04
NO871845D0 (no) 1987-05-04
CS313687A2 (en) 1990-11-14
AR247203A1 (es) 1994-11-30
HU206105B (en) 1992-08-28
AU7246687A (en) 1987-11-12
YU46422B (sh) 1993-10-20
NO171273C (no) 1993-02-17
KR870011122A (ko) 1987-12-21
DK226287A (da) 1987-11-06
DE3767029D1 (de) 1991-02-07
AU596175B2 (en) 1990-04-26
KR950001790B1 (ko) 1995-03-02
HUT48228A (en) 1989-05-29
US4855320A (en) 1989-08-08
SU1650009A3 (ru) 1991-05-15
CN87103274A (zh) 1988-01-20
EG18151A (en) 1992-08-30
NZ220188A (en) 1989-10-27
CN1016868B (zh) 1992-06-03
EP0247320B1 (de) 1990-12-27
EP0247320A3 (en) 1989-06-14
PT84824A (en) 1987-06-01
DE3615157A1 (de) 1987-11-12
JPS6322087A (ja) 1988-01-29
DK226287D0 (da) 1987-05-04
CA1270256A (en) 1990-06-12
EP0247320A2 (de) 1987-12-02
ATE59386T1 (de) 1991-01-15
NO871845L (no) 1987-11-06
PT84824B (pt) 1989-12-29
DD260699A5 (de) 1988-10-05

Similar Documents

Publication Publication Date Title
ES2003293A6 (es) Procedimiento de obtencion de 5-arilalquil-4-alcoxy-2(5h)-furanonas
PT95343A (pt) Processo para a preparacao de composicoes farmaceuticas contendo doses baixas de um agente anticoagulante oral tal como o warfarin e de um inibidor de plaquetas tal como o acido acetilsalilico,como ingredientes acticovos apropriadas para otratamento e/ou prevencao de doencas cardiacas
GT198900008A (es) Derivados de quinolina, quinazolina y cinolina.
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ES2043897T3 (es) Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
UA19303A (uk) Спосіб одержаhhя похідhих 2-аhіліhопіримідиhу
BR0009830A (pt) Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
ES2181725T3 (es) Inhibidores de hiv proteasa.
IT8821542A0 (it) Composti attivi come inibitori della biosintesi del colesterolo.
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
PT1089626E (pt) Agente de controlo de parasitas das plantas
ATE324039T1 (de) Verwendung von spinosad oder einer zusammensetzung enthaltend spinosad
ES2058244T3 (es) Procedimiento para produccion de avermectinas y cultivos para el mismo.
AR022358A1 (es) Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
ES2106042T3 (es) Inhibidores de la incorporacion de calcio.
DE19475001I2 (de) Anthelminthische Wirkstoffkombinationen.
FR2398067A1 (fr) Nouvelles 4-pyrones substituees en positions 2, 3 et 6 et medicament les contenant
ES2052533T3 (es) Composicion farmaceutica que comprende 2',3'-didesoxicitidin-2'-eno (2',3'-dideshidrocitidina) para tratar pacientes infectados con retrovirus.
ES2191211T3 (es) Uso de acido peracetico en piscicultura.
ES2075454T3 (es) Forma cristalina pura de rifapentina.
ES2012573A6 (es) Una composicion fungicida activa en el control de hongos fitopatogenos, en particular oomicetos.
ES2082074T3 (es) 1,3-difenil-2-propin-1-onas.
ES2096050T3 (es) Derivados amidas del acido piridiltiazolidincarboxilico, su preparacion y sus usos.
FI920428A0 (fi) Ett podofyllotoxinpreparat som innehaoller triglyserider.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20050505